Serotonergic mechanisms enhance platelet-mediated thrombogenicity

Thrombosis and Haemostasis

Volumn 102, Issue 3, 2009, Pages 511-519

  Galan, Ana M ^a   Lopez Vilchez, Irene ^a   Diaz Ricart, Maribel ^a   Navalon, Fulgencio ^a   Gomez, Esther ^b   Gasto, Cristobal ^b   Escolar, Gines ^a  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

Platelet pharmacology; Platelet physiology; Serotonin; Thrombogenesis

Indexed keywords

ADENOSINE DIPHOSPHATE; CALCIUM ION; CITALOPRAM; DALTEPARIN; PADGEM PROTEIN; SEROTONIN;

ANIMAL TISSUE; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; FIBRIN DEPOSITION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; THROMBIN TIME; THROMBOCYTE ACTIVATION; THROMBOCYTE MEMBRANE; THROMBOCYTE RICH PLASMA; THROMBOGENESIS; THROMBOGENICITY;

ADENOSINE DIPHOSPHATE; BLOOD PLATELETS; CALCIUM; CELL ADHESION; COAGULANTS; FLOW CYTOMETRY; HUMANS; P-SELECTIN; PERFUSION; PLATELET ACTIVATION; PLATELET-RICH PLASMA; SEROTONIN; THROMBELASTOGRAPHY; THROMBIN;

EID: 70449395449     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH08-12-0810     Document Type: Article

References (61)

1. White JG. Platelet secretory granules and associated proteins. Lab Invest 1993; 68: 497-498.
2. Mcnicol A, Israels SJ. Platelet dense granules: Structure, function and implications for haemostasis. Thromb Res 1999; 95: 1-18.
3. Hoyer D, Hannon JP, Martin GR. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav 2002; 71: 533-554. (Pubitemid 34219205)
4. Stratz C, Trenk D, Bhatia HS, et al. Identification of 5-HT3 receptors on human platelets: increased surface immunoreactivity after activation with adenosine diphosphate (ADP) and thrombin receptor-activating peptide (TRAP). Thromb Haemost 2008; 99: 784-786. (Pubitemid 351694238)
5. Carneiro AM, Blakely RD. Serotonin-, protein kinase C-, and Hic-5-associated redistribution of the platelet serotonin transporter. J Biol Chem 2006; 281: 24769-24780. (Pubitemid 44274251)
6. Nagatomo T, Rashid M, Abul MH, et al. Functions of 5-HT(2A) receptor and its antagonists in the cardiovascular system. Pharmacol Ther 2004; 104: 59-81. (Pubitemid 39410563)
7. Jin JG, Kunapuli SP. Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation. Proc Nat Acad Sci USA 1998; 95: 8070-8074. (Pubitemid 28326067)
8. Gomez-Gil E, Gasto C, Diaz-Ricart M, et al. Platelet 5-HT2A-receptor- mediated induction of aggregation is not altered in major depresion. Hum Psychopharmacol 2002; 17: 419-424. (Pubitemid 35469352)
9. Carney RM, Blumenthal JA, Catellier D, et al. Depression as a risk factor for mortality after acute myocardial infarction. Am J Cardiol 2003; 92: 1277-1281. (Pubitemid 37431134)
10. Carney RM, Freedland KE, Jaffe AS, et al. Depression as a risk factor for post-MI mortality. J Am Coll Cardiol 2004; 44: 472-474.
11. Escolar G, Diaz-Ricart M, Gomez-Gil E, et al. Serotonergic mechanisms: a potential link between affective disorders and cardiovascular risk. Drugs Today (Barc) 2005; 41: 721-743. (Pubitemid 43074782)
12. Carney RM, Freedland KE. Depression, mortality, and medical morbidity in patients with coronary heart disease. Biol Psychiatry 2003; 54: 241-247. (Pubitemid 37267854)
13. Schlienger RG, Meier CR. Effect of selective serotonin reuptake inhibitors on platelet activation : can they prevent acute myocardial infarction? Am J Cardiovasc Drugs 2003; 3: 149-162.
14. Maurer-Spurej E, Pittendreigh C, Solomons K. The influence of selective serotonin reuptake inhibitors on human platelet serotonin. Thromb Haemost 2004; 91: 119-128. (Pubitemid 38120206)
15. Sauer WH, Berlin JA, Kimmel SE. Effect of antidepressants and their relative affinity for the serotonin transporter on the risk of myocardial infarction. Circulation 2003; 108: 32-36.
16. Hron G, Kollars M, Binder BR, et al. Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation. J Am Med Assoc 2006; 296: 397-402. (Pubitemid 44127523)
17. Varadi K, Turecek PL, Schwarz HP. Thrombin generation assay and other universal tests for monitoring haemophilia therapy. Haemophilia 2004; 10 (Suppl 2): 17-21. (Pubitemid 40045406)
18. Anderson L, Quasim I, Soutar R, et al. An audit of red cell and blood product use after the institution of thromboelastometry in a cardiac intensive care unit. Transfus Med 2006; 16: 31-39.
19. Galan AM, Tonda R, Pino M, et al. Increased local procoagulant action: a mechanism contributing to the favorable hemostatic effect of recombinant FVIIa in PLT disorders. Transfusion 2003; 43: 885-892. (Pubitemid 36753938)
20. Escolar G, Bastida E, Castillo R, et al. Development of a computer program to analyze the parameters of platelet-vessel wall interaction. Haemostasis 1986; 16: 8-14. (Pubitemid 16140356)
21. Galan AM, Reverter JC, Bozzo J, et al. Assessment of potential thrombogenicity of coagulation factor IX concentrates in an in vitro model of human thrombogenesis. Thromb Res 1999; 96: 383-389.
22. Schins A, Honig A, Crijns H, et al. Increased coronary events in depressed cardiovascular patients: 5-HT2A receptor as missing link? Psychosom Med 2003; 65: 729-737.
23. Dale GL. Coated-platelets: an emerging component of the procoagulant response. J Thromb Haemost 2005; 3: 2185-2192.
24. Packham MA, Bryant NL, Guccione MA, et al. Effect of the concentration of Ca2+ in the suspending medium on the responses of human and rabbit platelets to aggregating agents. Thromb Haemost 1989; 62: 968-976.
25. Schneider DJ, Tracy PB, Mann KG, et al. Differential effects of anticoagulants on the activation of platelets ex vivo. Circulation 1997; 96: 2877-2883. (Pubitemid 27500085)
26. Kessels H, Beguin S, Andree H, et al. Measurement of thrombin generation in whole blood - the effect of heparin and aspirin. Thromb Haemost 1994; 72: 78-83. (Pubitemid 24202299)
27. Altman R, Scazziota A, DE Lourdes HM, et al. Recombinant factor VIIa reverses the inhibitory effect of aspirin or aspirin plus clopidogrel on in vitro thrombin generation. J Thromb Haemost 2006; 4: 2022-2027. (Pubitemid 44226784)
28. Escolar G, Galan AM, Mazzara R, et al. Measurement of platelet interactions with subendothelial substrata: relevance to transfusion medicine. Transfus Med Rev 2001; 15: 144-156. (Pubitemid 32303577)
29. Tonda R, Lopez-Vilchez I, Navalon F, et al. Platelets interact with tissue factor immobilized on surfaces: effects of shear rate. Eur J Clin Invest 2008; 38: 34-42. (Pubitemid 350301899)
30. Stahl SM. The human platelet. A diagnostic and research tool for the study of biogenic amines in psychiatric and neurologic disorders. Arch Gen Psychiatry 1977; 34: 509-516.
31. Rao GH, Escolar G, White JG. Epinephrine reverses the inhibitory influence of aspirin on plateletvessel wall interactions. Thromb Res 1986; 44: 65-74. (Pubitemid 16006895)
32. Roux SP, Sakariassen KS, Turitto VT, et al. Effect of aspirin and epinephrine on experimentally induced thrombogenesis in dogs. A parallelism between in vivo and ex vivo thrombosis models. Arterioscler Thromb 1991; 11: 1182-1191.
33. Ressler KJ, Nemeroff CB. Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. Depress Anxiety 2000; 12 (Suppl 1): 2-19. (Pubitemid 30823407)
34. Nutt D, Demyttenaere K, Janka Z, et al. The other face of depression, reduced positive affect: the role of catecholamines in causation and cure. J Psychopharmacol 2007; 21: 461-471.
35. Belcher PR, Drake-Holland AJ, Hynd J, et al. Dispersion of coronary artery thrombi by antagonism of platelet serotonin receptor in the dog. Cardiovasc Res 1992; 26: 292-296.
36. Nishihira K, Yamashita A, Tanaka N, et al. Inhibition of 5-hydroxytryptamine(2A) receptor prevents occlusive thrombus formation on neointima of the rabbit femoral artery. J Thromb Haemost 2006; 4: 247-255.
37. Uchiyama S, Ozaki Y, Satoh K, et al. Effect of sarpogrelate, a 5-HT(2A) antagonist, on platelet aggregation in patients with ischemic stroke: clinical-pharmacological dose-response study. Cerebrovasc Dis 2007; 24: 264-270. (Pubitemid 47295595)
38. Shinohara Y, Nishimaru K, Sawada T, et al. Sarpogrelate- Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS): A randomized, double-blind, aspirin-controlled trial. Stroke 2008; 39: 1827-1833.
39. Celada P, Puig M, Amargos-Bosch M, et al. The therapeutic role of 5-HT1A and 5-HT2A receptors in depression. J Psychiatry Neurosci 2004; 29: 252-265.
40. Shelton RC, Tollefson GD, Tohen M, et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 2001; 158: 131-134. (Pubitemid 32047260)
41. Li Q, Ma L, Innis RB, et al. Pharmacological and genetic characterization of two selective serotonin transporter ligands: 2-[2- (dimethylaminomethylphenylthio)]- 5-fluoromethylphenylamine (AFM) and 3-amino-4-[2-(dimethylaminomethyl-phenylthio)] benzonitrile (DASB). J Pharmacol Exp Ther 2004; 308: 481-486. (Pubitemid 38134208)
42. Shimbo D, Davidson KW, Haas DC, et al. Negative impact of depression on outcomes in patients with coronary artery disease: mechanisms, treatment considerations, and future directions. J Thromb Haemost 2005; 3: 897-908. (Pubitemid 41632817)
43. Atar D, Malinin A, Takserman A, et al. Escitalopram, but not its major metabolites, exhibits antiplatelet activity in humans. J Clin Psychopharmacol 2006; 26: 172-177. (Pubitemid 43740342)
44. Lichtman JH, Bigger JT, Jr., Blumenthal JA, et al. Depression and coronary heart disease: recommendations for screening, referral, and treatment: a science advisory from the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Psychiatric Association. Circulation 2008; 118: 1768-1775.
45. Maurer-Spurej E. Serotonin reuptake inhibitors and cardiovascular diseases: a platelet connection. Cell Mol Life Sci 2005; 62: 159-170. (Pubitemid 40193040)
46. van der Heijden FM, Tuinier S, Fekkes D, et al. Atypical antipsychotics and the relevance of glutamate and serotonin. Eur Neuropsychopharmacol 2004; 14: 259-265. (Pubitemid 38410961)
47. Sherwood A, Blumenthal JA, Trivedi R, et al. Relationship of depression to death or hospitalization in patients with heart failure. Arch Intern Med 2007; 167: 367-373. (Pubitemid 46333937)
48. Lesperance F, Frasure-Smith N, Koszycki D, et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial. J Am Med Assoc 2007; 297: 367-379. (Pubitemid 46155798)
49. Glassman AH, O'connor CM, Califf RM, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. J Am Med Assoc 2002; 288: 701-709.
50. Taylor CB, Youngblood ME, Catellier D, et al. Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. Arch Gen Psychiatry 2005; 62: 792-798. (Pubitemid 41002762)
51. Serebruany VL, Glassman AH, Malinin AI, et al. Selective serotonin reuptake inhibitors yield additional antiplatelet protection in patients with congestive heart failure treated with antecedent aspirin. Eur J Heart Fail 2003; 5: 517-521.
52. Meijer WE, Heerdink ER, Nolen WA, et al. Association of risk of abnormal bleeding with degree of serotonin reuptake inhibition by antidepressants. Arch Intern Med 2004; 164: 2367-2370.
53. de Abajo FJ, Montero D, Rodriguez LA, et al. Antidepressants and risk of upper gastrointestinal bleeding. Basic Clin Pharmacol Toxicol 2006; 98: 304-310.
54. Atar D, Malinin A, Pokov A, et al. Antiplatelet properties of escitalopram in patients with the metabolic syndrome: a dose-ranging in vitro study. Neuropsychopharmacology 2007; 32: 2369-2374. (Pubitemid 47587669)
55. Steiner JA, Carneiro AM, Blakely RD. Going with the Flow: Trafficking-Dependent and -Independent Regulation of Serotonin Transport. Traffic 2008; 9: 1393-1402.
56. Blakely RD, Ramamoorthy S, Schroeter S, et al. Regulated phosphorylation and trafficking of antidepressant- sensitive serotonin transporter proteins. Biol Psychiatry 1998; 44: 169-178. (Pubitemid 28378299)
57. Frankhauser P, Baranyai R, Ahrens T, et al. Platelet surface P-selectin expression is highly correlated with serotonin transporter density in human subjects. Thromb Haemost 2008; 100: 1201-1203.
58. Quick MW. Regulating the conducting states of a mammalian serotonin transporter. Neuron 2003; 40: 537-549.
59. Ren Q, Barber HK, Crawford GL, et al. Endobrevin/VAMP-8 is the primary v-SNARE for the platelet release reaction. Mol Biol Cell 2007; 18: 24-33. (Pubitemid 46066707)
60. Walther DJ, Peter JU, Winter S, et al. Serotonylation of Small GTPases Is a Signal Transduction Pathway that Triggers Platelet [alpha]-Granule Release. Cell 2003; 115: 851-862. (Pubitemid 38058497)
61. Carneiro AM, Cook EH, Murphy DL, et al. Interactions between integrin alphaIIbbeta3 and the serotonin transporter regulate serotonin transport and platelet aggregation in mice and humans. J Clin Invest 2008; 118: 1544-1552.